Perrigo Company plc announced that Opill has shipped to major retailers and pharmacies and will be available on shelves nationwide and online later this month. Approved by the U.S. Food and Drug Administration (FDA) for OTC use for all ages in July 2023, Opill is the first-ever daily birth control pill available without a prescription in the U.S. Opill is now available for pre-order from select online retailers and is expected to be on store shelves at major retailers nationwide in the coming weeks. Consumers will have the opportunity to purchase Opill in a variety of sizes in stores to best meet their needs, including one-month and three-month packs, with a manufacturer's suggested retail price (MSRP) of $19.99 and $49.99, respectively.

Additionally, Opill will be available for purchase at Opill.com at a price of $49.99 for a three-month supply and $89.99 for a six-month supply. When taken as directed, Opill® is 98% effective, making it the most effective birth control method available OTC. Almost half (45%) of the 6.1 million pregnancies in the U.S. each year are unintended, and for many, there are barriersto accessing more effective birth control options until now only available by prescription?including scheduling a provider visit, transportation and cost barriers or lack of insurance.

Opill can benefit a broad reproductive age population who want a safe and effective option to avoid pregnancy that is easy and convenient to access. Those who face barriers to initiating use of effective methods and continuing consistent use once started can benefit the most from Opill®. To maximize the impact and accessibility of Opill, Perrigo has sought to ensure both the affordability and availability of Opill® on major retailers' shelves across the country and online.

Opill® may also be eligible to be paid or reimbursed through Flexible Spending or Health Savings Accounts (also known as FSAs/HSAs). OTC drugs are now generally reimbursable under HSA and FSA plans, subject to the specific details and limitations of individual employers' plans.